Last Price
2.029
Today's Change
-0.08 (3.79%)
Day's Change
1.96 - 2.08
Trading Volume
246,572
Market Cap
1 Million
Shares Outstanding
841,240
Avg Volume
1,641,146
Avg Price (50 Days)
3.23
Avg Price (200 Days)
7.02
PE Ratio
-0.01
EPS
-147.00
Earnings Announcement
12-Sep-2024
Previous Close
2.11
Open
2.06
Day's Range
1.96 - 2.08
Year Range
1.835 - 40.05
Trading Volume
246,572
1 Day Change
-3.79%
5 Day Change
-6.88%
1 Month Change
-7.73%
3 Month Change
-58.57%
6 Month Change
-81.88%
Ytd Change
-77.93%
1 Year Change
-94.14%
3 Year Change
-99.51%
5 Year Change
-99.90%
10 Year Change
-99.90%
Max Change
-99.90%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.